Sobi announces FDA approval of Doptelet for pediatric thrombocytopenia patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Should l Buy ?
FDA Approval: Sobi North America received FDA approval for Doptelet to treat thrombocytopenia in pediatric patients aged one year and older with chronic immune thrombocytopenia, including a new formulation for children under six years old.
Study Results: The approval was based on the AVA-PED-301 study, which demonstrated that 27.8% of patients treated with Doptelet achieved a durable platelet response, while common adverse reactions included viral infections and nasopharyngitis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
